Loading clinical trials...

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260•Galderma R&D

View on ClinicalTrials.gov

Summary

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•\- Male or female at least 18 years of age.

Exclusion Criteria

•Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
•Anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational product).
•Female who is pregnant, breast feeding, or intends to conceive a child during the study.
•Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP) or any botulinum toxin serotype.

Locations (30)

Total Skin and Beauty Dermatology Center, PC

Birmingham, Alabama, United States

Investigate MD, LLC.

Scottsdale, Arizona, United States

Center for Dermatology Clinical Research, Inc.

Fremont, California, United States

Rejuva Medical Aesthetics, LLC

Los Angeles, California, United States

Westside Aesthetics

Los Angeles, California, United States

Marcus Facial Plastic Surgery

Redondo Beach, California, United States

The Maas Clinic Research Center

San Francisco, California, United States

ArteMedica

Santa Rosa, California, United States

AboutSkin Research, LLC

Greenwood Village, Colorado, United States

Modern Dermatology PC

Westport, Connecticut, United States

Key Dates

Start Date

January 27, 2020

Primary Completion Date

April 12, 2021

Completion Date

May 21, 2021

Last Updated

June 18, 2023

Enrollment

902

ACTUAL participants

Conditions

Glabellar LinesLateral Canthal Lines

Interventions

botulinum toxin neuromodulator

BIOLOGICAL

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Inclusion Criteria

Exclusion Criteria

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

A Study to Evaluate AI-09 In Participants With Glabellar Lines

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

ET-01 in Subjects With Lateral Canthal Lines, LCL-210